Icalcaprant[1] (developmental code name CVL-354) is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.

[2] It acts as a selective antagonist of the κ-opioid receptor.

[3] It was originated by Pfizer and is under development by Cerevel Therapeutics.

[2] As of September 2022, icalcaprant is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.

This drug article relating to the nervous system is a stub.